Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial

Circulation: Heart Failure

Volumn 9, Issue 3, 2016, Pages

  Lewis, Eldrin F ^a   Kim, Hae Young ^b   Claggett, Brian ^a   Spertus, John ^c   Heitner, John F ^d   Assmann, Susan F ^b   Kenwood, Christopher T ^b   Solomon, Scott D ^a   Desai, Akshay S ^a   Fang, James C ^e   McKinlay, Sonia A ^b   Pitt, Bertram A ^f   Pfeffer, Marc A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d NEW YORK METHODIST HOSPITAL   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

clinical trial; heart failure; predictors; preserved ejection fraction; quality of life

Indexed keywords

SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; AGE; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); EQ5D VISUAL ANALOG SCALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SMOKING; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; ARGENTINA; BRAZIL; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GEORGIA (REPUBLIC); HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ARGENTINA; BRAZIL; CANADA; DOUBLE-BLIND METHOD; FEMALE; GEORGIA (REPUBLIC); HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; RISK FACTORS; RUSSIA; SPIRONOLACTONE; STROKE VOLUME; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 84962591491     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001937     Document Type: Article

References (37)

1. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW., American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013 61 e78 e140
2. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL, Cardiovascular Health Study Research Group Importance of heart failure with preserved systolic function in patients > or =65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001 87 413 419
3. Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007 9 83 91. doi: 10.1016/j.ejheart.2006.10.012.
4. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B, CHARM committees and investigators Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003 5 261 270
5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 359 2456 2467. doi: 10.1056/NEJMoa0805450.
6. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 370 1383 1392. doi: 10.1056/NEJMoa1313731.
7. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 362 777 781. doi: 10.1016/S0140-6736(03)14285-7.
8. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013 309 781 791. doi: 10.1001/jama.2013.905.
9. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013 309 1268 1277. doi: 10.1001/jama.2013.2024.
10. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM., Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011 4 27 35. doi: 10.1161/CIRCHEARTFAILURE.109.932996.
11. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA., Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011 162 966 972.e10. doi: 10.1016/j.ahj.2011.09.007.
12. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, Boineau R, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Lewis EF, Markov V, O'Meara E, Kobulia B, Shaburishvili T, Solomon SD, Pitt B, Pfeffer MA, Li R., Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013 6 184 192. doi: 10.1161/CIRCHEARTFAILURE.112.972794.
13. Green CP, Porter CB, Bresnahan DR, Spertus JA., Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000 35 1245 1255
14. Brazier J, Jones N, Kind P., Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993 2 169 180
15. Juniper EF, Guyatt GH, Willan A, Griffith LE., Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994 47 81 87
16. Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, Dávila-Román VG, Mann DL, Spertus JA., Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail 2013 6 1139 1146. doi: 10.1161/CIRCHEARTFAILURE.113.000359.
17. Hauptman PJ, Masoudi FA, Weintraub WS, Pina I, Jones PG, Spertus JA, Cardiovascular Outcomes Research Consortium Variability in the clinical status of patients with advanced heart failure. J Card Fail 2004 10 397 402
18. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS, Cardiovascular Outcomes Research Consortium Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005 150 707 715. doi: 10.1016/j.ahj.2004.12.010.
19. Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC, Locatelli F, Parfrey PS, TREAT Investigators Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol 2011 6 845 855. doi: 10.2215/CJN.06450710.
20. Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD., Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail 2014 2 159 165. doi: 10.1016/j.jchf.2013.12.003.
21. Le QA, Doctor JN, Zoellner LA, Feeny NC., Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT). Health Qual Life Outcomes 2013 11 59. doi: 10.1186/1477-7525-11-59.
22. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW., Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001 20 1016 1024
23. Lewis EF., Assessing the impact of heart failure therapeutics on quality of life and functional capacity. Curr Treat Options Cardiovasc Med 2013 15 425 436. doi: 10.1007/s11936-013-0249-2.
24. Lewis EF., Still at the drawing board: improving quality of life in heart failure. Circ Heart Fail 2012 5 137 139. doi: 10.1161/CIRCHEARTFAILURE.112.966861.
25. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B., Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015 131 34 42. doi: 10.1161/CIRCULATIONAHA.114.013255.
26. O' Meara E LE, Granger C, Dunlap ME, McKelvie RS, Probstfield JI, Young J, Michelson E, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA., Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Failure 2005 7 650 656
27. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010 376 875 885. doi: 10.1016/S0140-6736(10)61198-1.
28. Veazie PJ, Noyes K, Li Q, Hall WJ, Buttaccio A, Thevenet-Morrison K, Moss AJ., Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol 2012 60 1940 1944. doi: 10.1016/j.jacc.2012.06.054.
29. Reynolds MR, Magnuson EA, Wang K, Thourani VH, Williams M, Zajarias A, Rihal CS, Brown DL, Smith CR, Leon MB, Cohen DJ, PARTNER Trial Investigators Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol 2012 60 548 558. doi: 10.1016/j.jacc.2012.03.075.
30. Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ, Surgical Treatment for Ischemic Heart Failure (STICH) Trial Investigators Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. Am Heart J 2009 157 837 844, 844.e1. doi: 10.1016/j.ahj.2009.03.008.
31. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O'Connor CM, Weinfurt KP, HF-ACTION Investigators Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009 301 1451 1459. doi: 10.1001/jama.2009.457.
32. Lewis EF TS, Stevenson LW., Patients with preference to trade time for better health or poorer quality of life have a higher mortality rate. J Cardiac Failure 2002 8 S14
33. Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL., Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 2013 15 1113 1121. doi: 10.1093/eurjhf/hft071.
34. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA, American Heart Association; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012 125 1928 1952. doi: 10.1161/CIR.0b013e31824f2173.
35. Hamo CE, Heitner JF, Pfeffer MA, Kim HY, Kenwood CT, Assmann SF, Solomon SD, Boineau R, Fleg JL, Spertus JA, Lewis EF., Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail 2015 8 268 277. doi: 10.1161/CIRCHEARTFAILURE.114.001838.
36. Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F, Konstam MA, Spertus JA., Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 2011 4 389 398. doi: 10.1161/CIRCOUTCOMES.110.958009.
37. Volz A, Schmid JP, Zwahlen M, Kohls S, Saner H, Barth J., Predictors of readmission and health related quality of life in patients with chronic heart failure: a comparison of different psychosocial aspects. J Behav Med 2011 34 13 22. doi: 10.1007/s10865-010-9282-8.